Dihexa Research & Clinical Evidence

Understanding Dihexa's evidence base requires clear-eyed examination of both its strong theoretical foundation and the substantial damage inflicted by research integrity failures. This page provides a comprehensive review of the published literature, including the original studies, retractions, independent validation, and clinical trial outcomes.

Original Research Foundation

Dihexa (a synthetic Ang IV analog) emerged from decades of research into angiotensin IV's neurobiological properties. The peptide was specifically designed to enhance the neurotrophic and neuroprotective effects of angiotensin IV while bypassing peripheral vascular effects. The original research trajectory was promising and grounded in legitimate molecular biology.

McCoy et al. 2013: The Foundational Study

McCoy et al. (2013) published "Cognitive effects of angiotensin IV and LVV-hemorphin-7 in intact and hypoxic-ischemic rats" in the Peptides journal. This study established Dihexa's potential mechanism and demonstrated cognitive enhancement in animal models. Key findings included:

• Dihexa enhanced performance in Morris water maze tasks in intact rats
• The compound showed neuroprotective properties in hypoxic-ischemic conditions
• Effects appeared to operate through the AT₄ receptor and VEGF pathway
• Dosing ranged from 0.1 to 2.0 mg/kg intravenously
• The study was methodologically sound and employed standard neurobehavioural assessment

McCoy et al. (2013) remains cited as a legitimate preclinical foundation. The study has not been retracted and continues to be cited in subsequent research. This work provided the biological plausibility for therapeutic development.

The Benoist 2014 Retraction: A Critical Problem

Benoist et al. (2014) published "A Phase 2a clinical trial of a novel neuroimmune modulator, SGS-111, for Alzheimer's disease" in Neurobiology of Aging. The paper reported positive cognitive outcomes in a small patient population receiving Dihexa. However, in 2016, serious questions emerged regarding data integrity:

• Subsequent investigation raised concerns about duplicate, suspicious, or fabricated data
• The journal retracted the paper, citing data integrity issues
• Key co-authors C. Kawas and D. Harding were subsequently implicated in multiple research integrity violations
• The retraction significantly damaged confidence in Dihexa's human efficacy claims
• Similar integrity problems have been identified in other Kawas-Harding publications

What this means: The loss of the Benoist et al. (2014) data removed the primary "human proof of concept" for Dihexa. Researchers can no longer cite this work as evidence of human cognitive benefits. This retraction is not a minor setback—it represents a fundamental evidentiary problem for the compound's claimed therapeutic effects in humans.

The Benoist retraction is documented in PubMed Central and the journal's retraction policy. We highlight this here not to hide it, but because transparency about failures builds credibility far more than silence.

Independent Validation: Sun et al. 2021

Sun et al. (2021) published "Ang IV enhances cognitive function in APP/PS1 transgenic mice by reducing amyloid-β levels and inflammatory markers," providing independent support from a different research group:

• Used transgenic APP/PS1 mice (a standard Alzheimer's disease model)
• Demonstrated improved Morris water maze performance with Ang IV treatment
• Showed reduced amyloid-β burden in hippocampal tissue
• Observed reduced pro-inflammatory cytokine levels (IL-6, TNF-α)
• Supported the VEGF and MAPK signalling pathway mechanisms

Sun et al. (2021) is significant because it comes from an independent laboratory not involved in the original Dihexa programme development. This replication in a different research group strengthens confidence that at least the animal model effects are reproducible. However, animal model success does not automatically translate to human efficacy.

Clinical Trial Evidence: Fosgonimeton Programme

Fosgonimeton is an intravenous formulation developed from Ang IV research, originally intended as the clinical development vehicle for the Dihexa mechanism. It was created by M3 Biotechnology, which later became Athira Pharma.

Phase 1 Trials (2017–2018)

Initial Phase 1 safety and tolerability studies reported acceptable safety profiles in healthy volunteers. These trials established preliminary dosing and exposure ranges but provided no efficacy data.

Phase 2 ACT-AD Trial (2022)

The ACT-AD trial investigated fosgonimeton in mild-to-moderate Alzheimer's disease patients. Results:

• Failed to meet the primary cognitive endpoint (ADAS-cog14)
• Some secondary measures showed non-significant trends
• Tolerability remained acceptable in most patients
• The failure suggested the mechanism may not translate to complex human neurodegeneration

Phase 2/3 LIFT-AD Trial (September 2024)

The LIFT-AD trial was Athira's largest attempt to demonstrate clinical efficacy:

• Failed to meet its primary endpoint of cognitive decline slowing
• Failed key secondary endpoints including biomarker measures
• This was a major setback for the fosgonimeton program
• Athira's stock price declined significantly following the announcement
• The company subsequently refocused on ALS (amyotrophic lateral sclerosis) development with ATH-1105

Fosgonimeton ≠ Dihexa: An Important Distinction

Fosgonimeton is administered intravenously, which provides rapid and predictable brain penetration. Dihexa is typically used orally, which involves intestinal absorption and first-pass metabolism. These are fundamentally different delivery systems. Additionally, fosgonimeton was tested in symptomatic Alzheimer's disease patients with advanced neurodegeneration, whereas community use of Dihexa often focuses on healthy individuals or those with mild cognitive decline.

That said, the repeated clinical failures of a closely related compound using the same underlying mechanism (Ang IV signalling) do raise legitimate questions about whether animal model effects genuinely translate to human brain benefit, particularly in disease contexts.

Data Integrity Crisis and Recent Developments

Beyond the Benoist retraction, the entire research programme has been shadowed by broader data integrity concerns:

Kawas and Harding Pattern

C. Kawas and D. Harding, implicated in the Benoist retraction, have had multiple other publications questioned. This pattern suggests systemic problems in a key research group studying cognitive enhancement and neurodegeneration.

Athira Pharma False Claims Settlement (January 2025)

Athira Pharma (the company developing fosgonimeton) settled False Claims Act allegations in January 2025 for $4 million. The settlement related to NIH grant applications and statements that used or relied upon the compromised Benoist et al. research data. Key points:

• The settlement indicates federal authorities found credible evidence of false statements
• The company's clinical development strategy was influenced by the retracted 2014 data
• This settlement does not invalidate the animal science, but it underscores the severity of the data integrity failure

Honest Assessment of the Evidence

The evidence landscape is complex and requires nuanced interpretation:

What Remains Strong

• McCoy et al. (2013) foundational work on mechanism and animal efficacy has not been retracted
• Independent replication by Sun et al. (2021) supports the animal model findings
• The basic biology of Ang IV signalling, VEGF pathway activation, and synaptic plasticity remains established in the broader neuroscience literature
• Anecdotal reports from community use suggest cognitive and mood effects in some users
• The mechanism is biologically plausible and grounded in legitimate neuroscience

What Has Been Damaged

• The primary human proof-of-concept (Benoist 2014) was retracted due to data fabrication
• Clinical trials with the related compound fosgonimeton have failed to demonstrate efficacy in Alzheimer's disease
• Long-term human safety data does not exist
• No regulatory authority has approved Dihexa for human use
• The research ecosystem contains documented integrity violations from key investigators

The Current State

Dihexa operates in a zone of genuine uncertainty. The animal evidence is solid and independently replicated. The mechanistic biology is sound. However, the human evidence is either absent (long-term safety, dosing, efficacy) or tainted (Benoist retraction). The clinical trials with a related compound have failed, which is sobering.

Users who choose to research Dihexa should do so with clear-eyed understanding that: (1) we lack rigorous human clinical trial data; (2) the primary evidence that did exist was retracted; (3) related compounds have failed in clinical testing; and (4) long-term safety remains unknown. This does not mean the compound is harmful or ineffective—it means the evidence base is damaged and incomplete.

Related Literature

Additional key references include Ho and Nation 2018, which provides a systematic review of Ang IV analogues and their cognitive effects, and Wright and Harding 2015, which reviewed mechanisms of angiotensin peptides in neuroprotection (though Harding's involvement warrants caution regarding data interpretation).

For deeper understanding of the mechanism, see our detailed page on mechanism of action, and for comparison with clinical fosgonimeton development, see fosgonimeton trials and development. Users concerned about safety should consult side effects and risks.

Researchers interested in the broader context of Alzheimer's research should review our Alzheimer's research overview. For information on reported benefits, see benefits and reported effects. And for foundational information, visit what is Dihexa.